The effects on IFN signaling observed at the 24-hour time point were largely abrogated in the late cohort (≥72 hours), with the notable exception of one patient sample (patient 13; lip/chin tumor, local disease; HPV status, negative; smoking status, previous) that had sustained expression of ISG15 at clearly discernible sites exposed to dazostinag alone and in all triple combination sites (Supplementary Fig. S6). This evidence concerns the gene ISG15 and neoplasm.